YOKNEAM, Israel, Oct. 17, 2017 /PRNewswire/ -- Lumenis Ltd.,
the world's largest energy-based medical device company for
surgical, aesthetic and ophthalmic applications, announced today
that it will share new clinical data on its CO2
laser-based FiberLase™ for minimally-invasive treatment of
endometriosis at the European Society for Gynecological Endoscopy
(ESGE) 26th Annual Congress, October 18- 21 at the Sueno Hotel Belek &
Convention Center in Antalya, Turkey.
Endometriosis is a disease that affects roughly 10% of the
world's female population. While the etiology of the disease is
still unclear, treatment options exist and vary between symptomatic
ease, hormonal supplements and hysterectomy when fertility is no
longer of concern. Approximately 85% of endometriosis patients are
diagnosed with ovarian endometriosis; these cases require delicate
and precise treatment options to preserve fertility.
Lumenis has collaborated with leading surgeons worldwide to
develop an advanced surgical CO2 FiberLase™ laser
procedure, which has been demonstrated to remove endometriosis
lesions very delicately and precisely without harming the ovarian
reserve. Recent studies1-6 show the treatment results in
fast recovery time, less inflammation and pain, low risk of
infection and low rate of side effects such as surgery-related
adhesions. Patients experience immediate improvement in their
quality of life, higher rates of fertility preservation and lower
disease recurrence rates compared to RF technology.
At the ESGE Annual Congress, Lumenis will highlight its
innovations in treating endometriosis, including the advanced
surgical CO2 lasers, UltraPulse® DUO and AcuPulse™ DUO.
These laser systems utilize both Free Beam laser delivery and the
flexible FiberLase™ fiber, designed to operate precisely around
delicate pelvic anatomy with minimal thermal damage while keeping
healthy tissue intact, significantly improving symptoms and quality
of life while helping to preserve and protect fertility.
Lumenis will host an industry symposium and share the results of
the recent study on the efficacy of the AcuPulse™ DUO for removal
of endometrial tissue around the ovaries while preserving ovarian
antral follicle count and anti-Müllerian hormone, both necessary
for fertility. Authors Prof. Massimo
Candiani and Dr. Jessica
Ottolina, and their colleagues will present results of the
study titled, "Positive Effects on Ovarian Reserve When Using
CO2 Laser Vaporization Versus Cystectomy for the
Treatment of Ovarian Endometrioma: A Prospective Randomized
Clinical Trial."
The study's author, Prof. Massimo
Candiani, Director of Obstetrics and Gynecology at the San
Raffaele Hospital in Milan, said,
"I consider the CO2 laser a valuable tool in the
treatment of pelvic and ovarian endometriosis, where I can easily
use it for excision and vaporization. When using the CO2
laser, I can achieve precision and safety and, most importantly,
preservation of the ovarian functionality."
"At Lumenis, we take great pride in our company's commitment and
continuous innovation in women's health technology," said Lumenis
CEO Tzipi Ozer-Armon. "We are very
excited to share the clinical and technological advances with our
partners and colleagues at the ESGE Annual Congress."
During the ESGE Annual Congress, attendees can visit Lumenis at
booth #20 to gain hands-on experience with the Lumenis
CO2 laser solutions and attend the company's range of
engaging symposia and presentations:
- Scientific session: "Positive Effects on Ovarian Reserve When
Using CO2 Laser Vaporization Versus Cystectomy for the
Treatment of Ovarian Endometrioma: A Prospective Randomized
Clinical Trial," Prof. Massimo
Candiani and Dr. Jessica
Ottolina. Session type: "best selected abstracts 2" 19
October, 08:30 a.m. - 10:30 a.m., 2
Hall Orkide 2
- Symposium: "Benefits of CO2 Laser in the Treatment
of Endometriosis," Panel members:Prof. Michelle Nisolle, Prof.
Massimo Candiani, Dr. Yücel Karaman,
Prof. Okolo, Dr. Mariona Rius , Dr.
Jessica Ottolina and Dr. Lotfi , who
will present two procedures using CO2 FiberLase fiber.
The colleagues will have a panel discussion on the benefits of the
treatment protocol. 19 October, 10:30 a.m. -
11:30 a.m., 2 Hall Orkide 2
- Scientific session: "Spontaneous Pregnancy Rates Following
a Laparoscopic CO2 Laser Surgery for Endometriosis," Dr.
Yücel Karaman. Session type: "Free Communication l
Laparoscopic Surgery", 20 October, 10:30
a.m. – 12:00 p.m., 4 Hall
Kardelen 2. Free Communication l Laparoscopic SurgeryLumenis
Advisory Board Meeting: "Consensus on The Gold Standard of
Treatment for Endometriosis"
Lumenis will also introduce attendees to www.gynhealth.com, a
website created by the company to educate endometriosis patients
and their families on the disease and its surgical treatment
options.
About Lumenis
Lumenis is the world's largest energy-based medical device
company for surgical, aesthetic and ophthalmic applications in the
area of minimally invasive clinical solutions. Regarded as a
world-renowned expert in developing and commercializing innovative
energy-based technologies, including Laser, Intense Pulsed Light
(IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis'
ground-breaking products have redefined medical treatments and have
set numerous technological and clinical gold-standards. Lumenis has
successfully created solutions for previously untreatable
conditions, as well as designed advanced technologies that have
revolutionized existing treatment methods. www.lumenis.com
References:
- Adelman MR, Tsai LJ, Tangchitnob
EP, Kahn BS, 2013.J Obstet Gynaecol,33(3): 225-31
- Wang Z, Chocat N, 2010. Curr Pharm Biotechno,
11(4):384-97.
- Bailey AP, Lancerotto L, Gridley C, Orgill DP, Nguyen H,
Pescarini E, Lago G, Gargiulo AR, 2014. J Minim Invasive Gynecol,
21(6):1103-9
- Schipper E, Nezhat C, 2012. Int J Womens Health ;4:383- 93
- Tsolakidis D, Pados G, Vavilis D, Athanatos D, Tsalikis T,
Giannakou A, Tarlatzis BC, 2010. Fertil Steril, 94(1):71-7
- Meuleman C, D'Hoore A, Van Cleynenbreugel B, Beks N, D'Hooghe
T, 2009. Reprod Biomed Online ;18(2):282-9
MEDIA CONTACT
Kara
Stephens, Pascale Communications
Kara@pascalecommunications.com
407-765-1185
View original
content:http://www.prnewswire.com/news-releases/lumenis-to-highlight-the-positive-impact-of-its-fiberlase-co2-laser-treatment-for-ovarian-endometrioma-on-ovarian-reserve-300538145.html
SOURCE Lumenis Ltd